- Trials with a EudraCT protocol (291)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (11)
291 result(s) found for: Pulmonary artery.
Displaying page 11 of 15.
EudraCT Number: 2020-003510-12 | Sponsor Protocol Number: GS-US-540-9012 | Start Date*: 2020-10-02 | |||||||||||
Sponsor Name:Gilead Sciences, Inc | |||||||||||||
Full Title: A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of COVID-19 in an Outpatient Setting | |||||||||||||
Medical condition: COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002779-24 | Sponsor Protocol Number: 3.089.17 | Start Date*: 2018-06-12 | ||||||||||||||||
Sponsor Name:University of Aberdeen [...] | ||||||||||||||||||
Full Title: A randomised, double-blind placebo controlled trial of the effectiveness of the beta-blocker bisoprolol in preventing exacerbations of chronic obstructive pulmonary disease. | ||||||||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004695-18 | Sponsor Protocol Number: RES-Q-HR | Start Date*: 2020-12-02 | ||||||||||||||||||||||||||
Sponsor Name:Heinrich-Heine-University Düsseldorf | ||||||||||||||||||||||||||||
Full Title: Reconvalescent plasma/Camostat mesylate early in Sars-CoV-2 Q-PCR positive high risk individuals | ||||||||||||||||||||||||||||
Medical condition: The novel coronavirus designated SARS CoV-2, and the disease caused by this virus designated COVID-19. No treatment is available for early disease stages and non-hospitalized patients to date. This... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-003870-27 | Sponsor Protocol Number: RA2363 | Start Date*: 2008-10-08 |
Sponsor Name:University of Nottingham | ||
Full Title: ENOS: Efficacy of Nitric Oxide in Stroke. Estudio ENOS: Eficacia del óxido nítrico en el ictus | ||
Medical condition: Hipertensión en el ictus agudo | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) DK (Completed) SE (Completed) GR (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-021793-12 | Sponsor Protocol Number: AC-052-374 | Start Date*: 2011-04-04 | |||||||||||||||||||||
Sponsor Name:Actelion Pharmaceuticals Ltd. | |||||||||||||||||||||||
Full Title: A prospective, multicenter, open-label extension of FUTURE 3 to assess the safety, tolerability and efficacy of the pediatric formulation of bosentan two versus three times a day in children with p... | |||||||||||||||||||||||
Medical condition: Pulmonary arterial hypertension (PAH) in children | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) HU (Completed) CZ (Completed) FR (Ongoing) NL (Completed) ES (Completed) IT (Completed) PL (Completed) Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-000128-16 | Sponsor Protocol Number: 2011-003 | Start Date*: 2012-07-30 | |||||||||||
Sponsor Name:Onyx Therapeutics, Inc. | |||||||||||||
Full Title: A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma | |||||||||||||
Medical condition: Multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) HU (Completed) DE (Completed) IT (Completed) ES (Completed) SK (Completed) GR (Completed) CZ (Completed) AT (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001975-30 | Sponsor Protocol Number: BAY59-7939/17938 | Start Date*: 2016-01-12 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: Global multicenter, open-label, randomized, event-driven, active-controlled study comparing a rivAroxaban-based antithrombotic strategy to an antipLatelet-based strategy after transcatheter aortIc ... | |||||||||||||
Medical condition: Patients with severe aortic stenosis that require Transcatheter aortic valve replacement are at risk of thrombus formation. Rivaroxaban (oral-anticoagulant) may reduce this risk, without increasing... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) NO (Prematurely Ended) AT (Prematurely Ended) DK (Prematurely Ended) SE (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) FR (Prematurely Ended) CZ (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003453-13 | Sponsor Protocol Number: CE01-301 | Start Date*: 2014-06-18 | |||||||||||
Sponsor Name:Cempra Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in the Treatment of Ad... | |||||||||||||
Medical condition: Community-Acquired Bacterial Pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BG (Completed) LV (Completed) DE (Completed) ES (Completed) RO (Completed) SK (Completed) NL (Completed) SI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000827-13 | Sponsor Protocol Number: A5951001 | Start Date*: 2007-11-26 | |||||||||||
Sponsor Name:Pfizer Pharmaceutical Group | |||||||||||||
Full Title: LINEZOLID IN THE TREATMENT OF SUBJECTS WITH NOSOCOMIAL PNEUMONIA PROVEN TO BE DUE TO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS | |||||||||||||
Medical condition: MRSA Infection - Nosocomical Pneumenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) DE (Completed) ES (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002683-14 | Sponsor Protocol Number: DSE-EDO-01-15-EU | Start Date*: 2017-01-12 | |||||||||||
Sponsor Name:Daiichi Sankyo Europe GmbH | |||||||||||||
Full Title: Evaluation of the safety and efficacy of an edoxaban-based compared to a vitamin K antagonist-based antithrombotic regimen following successful percutaneous coronary intervention (PCI) with stent p... | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) IE (Completed) GB (Completed) NL (Completed) DE (Completed) LT (Completed) ES (Completed) AT (Completed) HU (Completed) PT (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-017082-39 | Sponsor Protocol Number: Bay 58-2667 / 14836 | Start Date*: 2010-02-01 | |||||||||||
Sponsor Name:Bayer Healthcare AG | |||||||||||||
Full Title: A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (50 μg/h, 100 μg/h, 150 μg/h) Given Intravenousl... | |||||||||||||
Medical condition: Acute Decompensated Chronic Congestive Heart Failure (ADHF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) IE (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) FR (Completed) GB (Prematurely Ended) IT (Prematurely Ended) CZ (Prematurely Ended) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001719-65 | Sponsor Protocol Number: CALC-SSc | Start Date*: 2018-12-10 |
Sponsor Name:University Medial Center Groningen | ||
Full Title: CALCification as an early marker of vasculopathy and organ involvement in Systemic Sclerosis CALC-SSc study | ||
Medical condition: Systemic sclerosis (SSc) is a rare progressive autoimmune disease hallmarked by severe vasculopathy. Patients are prone to enhanced calcification of skin and the vasculature. Active calcifications ... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-005336-23 | Sponsor Protocol Number: Baby-OSCAR | Start Date*: 2014-12-16 |
Sponsor Name:University of Oxford | ||
Full Title: Outcome After Selective Early Treatment for Closure of Patent Ductus Arteriosus in Pre-term Babies | ||
Medical condition: Patent ductus arteriosus of the newborn | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2007-000284-21 | Sponsor Protocol Number: 524E-CVD-9101-004 | Start Date*: 2007-11-08 | |||||||||||
Sponsor Name:York Hospitals NHS Foundation Trust [...] | |||||||||||||
Full Title: A multicentre, multinational randomised control trial of prophylactic low molecular weight heparin(LMWH) in high risk pregnant thrombophilic women | |||||||||||||
Medical condition: Thrombophilia in pregnancy. This is a multi-centre, multi-national randomised controlled trial of Low Molecular Weight Heparin to prevent pregnancy complications in high-risk pregnant thrombophi... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002367-34 | Sponsor Protocol Number: 29052016 | Start Date*: 2016-09-30 | |||||||||||
Sponsor Name:Hjertemedicinsk klinik, Rigshospitalet | |||||||||||||
Full Title: Beta 3 agonist treatment in heart failure (BEAT-HF II) | |||||||||||||
Medical condition: Heart Failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006614-37 | Sponsor Protocol Number: CryoStopPersAF | Start Date*: 2022-05-11 | |||||||||||
Sponsor Name:Region Örebro | |||||||||||||
Full Title: First-line cryoablation for early treatment of Persistent Atrial Fibrillation – a randomized study comparing early trigger isolation using the Cryoballoon versus antiarrhythmic medication. | |||||||||||||
Medical condition: Persistent symptomatic atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002699-42 | Sponsor Protocol Number: DANBLOCK | Start Date*: 2018-09-28 | |||||||||||
Sponsor Name:Bispebjerg Frederiksberg Hospital | |||||||||||||
Full Title: Danish trial of beta blocker treatment after myocardial infarction without reduced ejection fraction (DANBLOCK) | |||||||||||||
Medical condition: Myocardial infarction. We wish to test whether long-term treatment with betablocker (bisoprolol, carvedilol, metoprolol or nebivolol) leads to better prognosis than no treatment in patients sufferi... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-006439-12 | Sponsor Protocol Number: INSIGHT001:STARTDAIDSID#10619 | Start Date*: 2009-05-25 |
Sponsor Name:Regents of the University of Minnesota | ||
Full Title: Strategic Timing of AntiRetroviral Treatment(START) | ||
Medical condition: HIV Infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) FI (Completed) ES (Completed) DE (Completed) GB (GB - no longer in EU/EEA) GR (Completed) IT (Completed) SE (Completed) PT (Completed) IE (Completed) EE (Completed) NO (Completed) AT (Completed) CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-005022-18 | Sponsor Protocol Number: PACeS | Start Date*: 2022-07-26 | |||||||||||
Sponsor Name:Icahn School of Medicine at Mount Sinai | |||||||||||||
Full Title: Anticoagulation for New-Onset Post-Operative Atrial Fibrillation after CABG | |||||||||||||
Medical condition: New-Onset Post-Operative Atrial Fibrillation after CABG | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000397-23 | Sponsor Protocol Number: SLx-2101-07-04 | Start Date*: 2007-05-29 | |||||||||||
Sponsor Name:Surface Logix, Inc. | |||||||||||||
Full Title: A randomised, double blind, placebo-controlled, cross-over pilot study to examine the safety, tolerability and pharmacodynamic profile of repeat oral doses of SLx-2101 once daily for up to 14 days ... | |||||||||||||
Medical condition: Raynaud's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
